Completed PHASE1 INTERVENTIONAL NCT00001507

Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer

A Multi-Center Study of Paclitaxel/Cyclophosphamide and High Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Breast Neoplasm Neoplasm Metastasis

Interventions Baxter Isolex 3001 Stem Cell Selection System Ceprate SC Monoclonal Antibody 3A1 Monoclonal Antibody 95-5-49 Monoclonal Antibody 95-6-22

Updated 7 times since 2017 Last updated: Dec 20, 2018 Started: Jul 12, 1996 Primary completion: Jun 30, 1998 Completion: Jun 20, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Neoplasm and Neoplasm Metastasis, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States